Donate

Publication Details

Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm
Newer antibodies against CD20

Newer antibodies against CD20 (April 2020)

Newer antibodies against CD20 are beginning to offer alternatives to rituximab for some people with lymphoma. This factsheet covers: antibodies targeting CD20; ofatumumab (Arzerra®); obinutuzumab (Gazyvaro®). It considers who can have these antibodies, how they are given, possible side effects.

Author(s)
Lymphoma Action
Place of publication
Aylesbury
Publisher
Lymphoma Action
Date of publication
April 2020
Pages
10pp
Supplier
https://lymphoma-action.org.uk/
Subject(s)
Lymphomas, Biological therapies, Monoclonal antibodies, Ofatumumab, Arzerra®, Obinutuzumab, Gazyvaro®
Format
Factsheet
Language
English
Flesch readability score
48.0
Download this resource
Download this resource
Back to results
Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm
Donate

About this site

Macmillan sites

Right there with you

We're here to provide physical, financial and emotional support. So whatever cancer throws your way, we're right there with you. Contact us

Follow us

© Macmillan Cancer Support 2019 © Macmillan Cancer Support, registered charity in England and Wales (261017), Scotland (SC039907) and the Isle of Man (604). Also operating in Northern Ireland. A company limited by guarantee, registered in England and Wales company number 2400969. Isle of Man company number 4694F. Registered office: 89 Albert Embankment, London SE1 7UQ. VAT no: 668265007